Antimalarial pharmacology and therapeutics of atovaquone

Nixon, GL, Moss, DM, Shone, AE, Lalloo, DG ORCID: 0000-0001-7680-2200, Fisher, N, O'Neill, PM ORCID: 0000-0003-4338-0317, Ward, SA and Biagini, GA
(2013) Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy, 68 (5). pp. 977-985.

[img] Text
Atovaquone Review_JACs_Revised02.docx - Unspecified
Available under License Creative Commons Attribution.

Download (2MB)


Atovaquone is used as a fixed dose combination with proguanil (MalaroneTM), either for treating children and adults with uncomplicated malaria or as a chemoprophylaxis for preventing malaria in travellers. Indeed in the US, between 2009-2011, MalaroneTM prescriptions accounted for 70% of all antimalarial pre-travel prescriptions. In 2013 the patent for MalaroneTM will expire, potentially resulting in a wave of low-cost generics. Furthermore, the malaria scientific community has a number of antimalarial quinolones, with a related pharmacophore to atovaquone, at various stages of pre-clinical development. With this in mind, it is timely here to review the current knowledge of atovaquone, with the purpose of aiding decision making of clinicians and drug developers involved in the future use of atovaquone generics or atovaquone derivatives.

Item Type: Article
Additional Information: Nixon, Gemma L Moss, Darren M Shone, Alison E Lalloo, David G Fisher, Nicholas O'Neill, Paul M Ward, Stephen A Biagini, Giancarlo A England J Antimicrob Chemother. 2013 May;68(5):977-85. doi: 10.1093/jac/dks504. Epub 2013 Jan 4.## TULIP Type: Articles/Papers (Journal) ##
Subjects: ?? QD ??
Depositing User: Symplectic Admin
Date Deposited: 14 Apr 2015 16:02
Last Modified: 17 Dec 2022 01:27
DOI: 10.1093/jac/dks504
Related URLs: